article

UPDATE: The Cancer Drugs Fund

Posted: 1 March 2017 | | No comments yet

This page will be updated as the results from the Cancer Drugs Fund appraisal are announced by The National Institute of Health and Care Excellence (NICE).

This page will be updated as the results from the Cancer Drugs Fund appraisal are announced by The National Institute of Health and Care Excellence (NICE).

Originally introduced in 2011, The Cancer Drugs Fund (CDF) was established by the coalition Government in order to provide a means by which NHS patients in England could get cancer drugs that were not routinely available on the NHS.

In April 2016, NICE started to assess the cost and clinical effectiveness of every drug currently in the old CDF.

Speaking on the new process in March 2017, Sir Andrew Dillon, Chief Executive of NICE, said,  “The system is working well. Companies are cooperating well with our reviews and the good news for patients is that more cancer drugs than ever are being recommended for routine use. As drugs move off the CDF, we free up funding for new drugs coming down the pipeline, so patients will have faster access to promising cancer drugs and the NHS makes the most of its resources.”

Modified appraisal process

The appraisal process for CDF drugs now allows NICE to make one of three recommendations:

  1. Recommend for routine commissioning – YES
  2. Not recommended for routine commissioning – NO
  3. Recommended for use within the CDF – NEW

DRUG

INDICATION

YES/ NO/ CDF

Abiraterone

metastatic castration resistant prostate cancer

 

Albumin Bound Paclitaxel

advanced adenocarcinoma of the pancreas

 

Bendamustine

Chronic Lymphocytic Leukaemia OR low grade lymphoma OR mantle cell non-Hodgkin’s lymphoma OR relapsed multiple myeloma

 

Bevacizumab

recurrent or metastatic cervical cancer OR advanced breast cancer OR advanced colorectal cancer OR low grade gliomas of childhood OR advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer

 

Bortezomib

bortezomib naive relapsed multiple myeloma

 

Bosutinib

(Bosulif, Pfizer)

refractory chronic/ accelerated phase Chronic Myeloid Leukaemia

 YES

Routine NHS use

Brentuximab

refractory systemic anaplastic lymphoma OR relapsed or refractory CD30+ Hodgkin’s lymphoma

 

Cabazitaxel

castrate-resistant Metastatic Prostate Cancer

 

Cabozantinib (Cabometyx, Ipsen)

advanced renal cell carcinoma

NO

Unreliable evidence

Ceritinib (Zykadia, Novartis)

previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer

YES

Routine NHS use

Cetuximab  (Erbitux, Merck)

head and neck cancer OR metastatic colorectal cancer 

NO

Not cost-effective

Clofarabine

acute lymphoblastic leukaemia OR acute myeloblastic leukaemia

 

Crizotinib (Xalkori, Pfizer)

non-small cell lung cancer

YES

Routine NHS use

Dasatinib

Ph+ acute lymphoblastic leukaemia OR chronic/ accelerated phase chronic myeloid leukaemia

 

Enzalutamide

Metastatic Prostate Cancer

 

Eribulin (Halaven, Eisai)

advanced breast cancer

YES

Routine NHS use

Everolimus (Novartis)

advanced breast cancer AND renal cell carcinoma

YES

Routine NHS use

Ibrutinib

Chronic Lymphocytic Leukaemia OR Mantle Cell Lymphoma

 

Idelalisib

Chronic Lymphocytic Leukaemia

 

Lenalidomide

myelodysplastic syndromes (MDS) OR multiple myeloma

 

Nelarabine

T-cell acute lymphoblastic leukaemia OR refractory T-cell lymphoblastic non-Hodgkin’s lymphoma

 

Nivolumab (Opdivo, Bristol-Myers Squibb)

squamous and non-squamous advanced non-small-cell lung cancer

Case was not clear cut then YES

Routine NHS use

Ofatumumab

chronic lymphocytic leukaemi

 

Osimertinib (Tagrisso, AstraZeneca)

lung cancer

YES

Only on CDF

Panitumumab

metastatic colorectal cancer

 

Pegylated Liposomal Doxorubicin

Named sarcomas

 

Pemetrexed

(Alimta, Eli Lilly)

non-squamous non-small cell lung cancer

YES 

NHS routine use

Peptide Receptor Radionucleotide Therapy (Octreotate)

neuroendocrine tumours

 

Pertuzumab

locally advanced or metastatic breast cancer

 

Pomalidomide

relapsed and refractory multiple myeloma

 

Ponatinib

(Iclusig, Incyte Corporation)

Chronic Myeloid Leukaemia with T315I Mutation OR Ph+ Acute Lymphoblastic Leukaemia with T315I Mutation

YES

NHS routine use

Radium-223 Dichloride

castration-resistant prostate cancer

 

Regorafenib

gastro-intestinal stromal tumours (GIST)

 

Ruxolitinib

symptomatic splenomegaly in primary myelofibrosis OR post polycythaemia vera myelofibrosis OR post essential thrombocythaemia myelofibrosis

 

Sorafenib

hepatocellular carcinoma OR papillary or follicular thyroid cancer

 

Sunitinib

pancreatic neuroendocrine carcinomas

 

Temsirolimus

renal cell carcinoma

 

Trastuzumab Emtansine

HER2-positive locally advanced/ unresectable OR metastatic (Stage IV) breast cancer

 

Vandetinib

medullary thyroid cancer

 

Vismodegib

locally advanced or metastatic Basal Cell Carcinoma

 

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Send this to a friend